Discrepant elevation of sIL-2R levels in sarcoidosis patients with renal insufficiency

Sarcoidosis is a systemic, granulomatous disease that can manifest in multiple organs [1]. Several biomarkers are used to assess disease activity and monitor response to therapy, including soluble interleukin-2 receptor (sIL-2R) and angiotensin-converting enzyme (ACE) [2]. sIL-2R was previously show...

Full description

Saved in:
Bibliographic Details
Published inThe European respiratory journal Vol. 46; no. 1; pp. 277 - 280
Main Authors Verwoerd, Anouk, Vorselaars, Adriane D.M., van Moorsel, Coline H.M., Bos, Willem Jan W., van Velzen-Blad, Heleen, Grutters, Jan C.
Format Journal Article
LanguageEnglish
Published England 01.07.2015
Subjects
Biomarkers - blood
Diabetic Nephropathies - complications
Female
Fluorodeoxyglucose F18
Glomerular Filtration Rate
Glomerulonephritis, Membranous - complications
Heart Failure - complications
Humans
Male
Middle Aged
Nephrotic Syndrome - complications
Pilot Projects
Positron-Emission Tomography
Receptors, Interleukin-2 - blood
Regression Analysis
Renal Insufficiency - blood
Retrospective Studies
Sarcoidosis - blood
Sarcoidosis - complications
Online AccessGet full text

Cover

More Information
Summary:Sarcoidosis is a systemic, granulomatous disease that can manifest in multiple organs [1]. Several biomarkers are used to assess disease activity and monitor response to therapy, including soluble interleukin-2 receptor (sIL-2R) and angiotensin-converting enzyme (ACE) [2]. sIL-2R was previously shown to correlate with the amount of CD4+ T-lymphocytes in bronchoalveolar lavage fluid [3]. Furthermore, it was shown that sIL-2R >4000pg.mL-1 was a significant predictor of relapse after discontinuation of infliximab therapy and that sIL-2R is a suitable prognostic marker for disease progression [4, 5]. We observed, however, that in a small number of patients with co-existing renal insufficiency, sIL-2R can be disproportionately high without marked signs of disease activity based on 18F-fluorodeoxyglucose positron emission tomography (FDG-PET), ACE and the clinical presentation. The aim of this pilot study is therefore to evaluate the influence of renal function on sIL-2R levels to determine if and how the marker can be used in sarcoidosis patients with renal insufficiency. In order to further illustrate the discrepancy, we first describe two cases.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0903-1936
1399-3003
DOI:10.1183/09031936.00005315